ArticleFrontiers in immunology2025
Integrative multi-omics reveals energy metabolism-related prognostic signatures and immunogenetic landscapes in lung adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Energy metabolism (EM) is critically involved in driving tumor development, therapeutic resistance, and modulation of the immune response. However, its genetic basis and prognostic value in lung adenocarcinoma (LUAD) remain unclear. This study integrates multi-omics approaches to develop an EM-related prognostic model for assessing LUAD prognosis and uncovering relevant immunogenetic pathways. Methods: Differential analysis combined with Mendelian randomization was used to identify EM-related genes (EMRGs) with a causal link to LUAD, which were then used to build a prognostic model via machine learning. Nomogram integrating clinical features and risk model was developed to enhance prognostic accuracy. Subsequent analyses, including immune invasion, enrichment analysis, and tumor mutational burden (TMB), were conducted to explore biological associations. The heterogeneity and cell-specific expression of critical EMRGs were explored through single-cell RNA sequencing (scRNA-seq). The transcriptional levels of the chosen EMRGs were experimentally validated using reverse transcription quantitative PCR (RT-qPCR). Results: A prognostic model was established in our study using Random Survival Forest (RSF) machine learning (ML) algorithm. Survival outcomes were substantially lower in the high-risk group (HRG) than in the low-risk group (LRG), as reflected by an AUC value of 0.73. A nomogram incorporating this risk model outperformed one without it. Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG)-based analyses showed a significant enrichment of these genes in pathways linked to immune regulation and extracellular matrix (ECM) dynamics. An elevated TMB in HRG may predict a worse prognosis. Evaluation of pharmacologic susceptibility revealed enhanced drug sensitivity in the HRG, such as Cytotoxic Chemotherapy and Apoptosis-inducing small molecule inhibitors, etc. ScRNA-seq revealed that prognostic EMRGs were mainly enriched in T and NK cells, myeloid cells, and fibroblasts, suggesting their involvement in immune regulation and remodeling of the tumor microenvironment (TME). RT-qPCR confirmed their differential expression in LUAD and normal cell lines. Conclusions: This integrative model reveals the prognostic and therapeutic relevance of EMRGs in LUAD, presenting a novel structure for immunogenetic risk assessment and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.